مباشر

FierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 Endpoints NewsHikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug CellPaleogenomes reveal the evolutionary relationship between modern and cave lions Endpoints NewsLilly, Boehringer retrench in Germany on proposed health spending cuts Endpoints NewsSupreme Court sides with Hikma in 'skinny label' case FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Endpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinic BioPharma DiveAlnylam, Inceptive ink AI deal potentially worth $2B FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract Pharma Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times

Endpoints News ٤ يونيو ٢٠٢٦

Parabilis Medicines charts $413M IPO to back peptide pipeline

Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the d...

Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the drug developer follows through with its plans, that ...